Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Amortization of Deferred Charges (2022 - 2023)

Historic Amortization of Deferred Charges for Century Therapeutics (IPSC) over the last 2 years, with Q2 2023 value amounting to $38000.0.

  • Century Therapeutics' Amortization of Deferred Charges fell 5000.0% to $38000.0 in Q2 2023 from the same period last year, while for Dec 2023 it was $94000.0, marking a year-over-year decrease of 6845.64%. This contributed to the annual value of $94000.0 for FY2023, which is 6856.19% down from last year.
  • According to the latest figures from Q2 2023, Century Therapeutics' Amortization of Deferred Charges is $38000.0, which was down 5000.0% from $56000.0 recorded in Q1 2023.
  • In the past 5 years, Century Therapeutics' Amortization of Deferred Charges ranged from a high of $77000.0 in Q3 2022 and a low of $38000.0 during Q2 2023